<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154764</url>
  </required_header>
  <id_info>
    <org_study_id>CG100649-1-03</org_study_id>
    <nct_id>NCT01154764</nct_id>
  </id_info>
  <brief_title>Trial for Studying Pharmacokinetic Effects of Ketoconazole on CG100649</brief_title>
  <official_title>A Randomized, Open, Crossover Clinical Study to Investigate the Effects of Ketoconazole on the Pharmacokinetics of CG100649 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-labeled, randomization and 2x2 Cross trial to compare the
      pharmacokinetic effects between ketoconazole and CG100649 for healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Adverse Events The whole study discontinuation is determined based on the following
           criteria with Adverse Events classified using US NCI (National Cancer Institute) 'Common
           Terminology Criteria for Adverse Events (CTCAE)

        -  Pharmacokinetic assessment Real sampling times will be used to calculate pharmacokinetic
           parameters. Concentrations below the lower limit of quantification, samplings which are
           not applicable, or missing data will be substituted by &quot;&lt;LLOQ&quot;, &quot;NA&quot;, or &quot;MD&quot;
           respectively. Pharmacokinetic analyses will be performed on CG100649 only.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic evaluation</measure>
    <time_frame>2 month</time_frame>
    <description>AUClast, Cmax, tmax, AUCinf, t1/2β After administration, the concentration of CG100649 in Plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation-No adverse events</measure>
    <time_frame>2 month</time_frame>
    <description>BP, ECG, urinary electrolytes, Adverse events, vital signs, Fecal occult blood test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CG100649 and ketoconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649</intervention_name>
    <description>I period: CG 100649 single dose 6 mg II period: Ketoconalzole + CG100649 at the same time washout period: 42 days</description>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_label>CG100649 and ketoconazole</arm_group_label>
    <other_name>CG100649 and ketoconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649 and ketoconazole</intervention_name>
    <description>I period: ketoconazole 400 mg + CG100649 6 mg II period: CG 100649 single dose 6 mg washout period: 42 days</description>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_label>CG100649 and ketoconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19-55 years old and weight 50kg above with within 20% of ideal body weight

          2. No significant chronic/congenital disease

          3. Normal results for lab test

          4. Ability of informed consent

        Exclusion Criteria:

          1. History or presence of liver, kidney, or nervous system disease, respiratory
             disorders, endocrinological disorders, hemato-oncologic, cardiovascular or psychiatric
             or cognitive disorders.

          2. History of gastrointestinal disorders (bleeding, ulceration, hemorrhoids, piles) or
             disorders of absorption, distribution, metabolism, excretion.

          3. History of known hypersensitivity to drugs including CG100649.

          4. After taking a rest in sitting position for 3 minutes, subjects who have low blood
             pressure (Systolic BP ≤ 90 mmHg or Diastolic BP ≤ 50 mmHg) or high blood pressure
             (Systolic BP ≥ 150 mmHg or Diastolic BP ≥ 100 mmHg).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Seok Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul Asan medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>February 13, 2013</last_update_submitted>
  <last_update_submitted_qc>February 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy male volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 17, 2016</submitted>
    <returned>October 10, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

